NF-κB, macrophage migration inhibitory factor and cyclooxygenase-inhibitions as likely mechanisms behind the acetaminophen- and NSAID-prevention of the ovarian cancer

Neoplasma

Volumn 51, Issue 4, 2004, Pages 239-247

  Altinoz, M A ^a,b   Korkmaz, R ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MEMORIAL HOSPITAL   (Turkey)

Author keywords

Acetaminophen; Cyclooxygenase; Macrophage migration inhibitory factor MIF; Nf kappaB; NSAID; Ovarian cancer; Prevention

Indexed keywords

ACETYLSALICYLIC ACID; CHEMOKINE; CYCLOOXYGENASE 2; DICLOFENAC; GROWTH FACTOR; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHENOL DERIVATIVE; PROSTAGLANDIN SYNTHASE INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR; UROKINASE; VASCULOTROPIN; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; CYCLOOXYGENASE 3; CYCLOOXYGENASE-3; GLUTATHIONE; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PTGS2 PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ATROPHY; AUTOCRINE EFFECT; CANCER INVASION; CANCER RISK; COLON CANCER; ENZYME INHIBITION; HUMAN; MOUSE; NONHUMAN; OVARY CANCER; OVULATION; SHORT SURVEY; FEMALE; INFLAMMATION; METABOLISM; OVARY TUMOR; REVIEW;

ACETAMINOPHEN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; FEMALE; GLUTATHIONE; HUMANS; INFLAMMATION; ISOENZYMES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MEMBRANE PROTEINS; NF-KAPPA B; OVARIAN NEOPLASMS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 3142717392     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (112)

1. ABIRU S, NAKAO K, ICHIKAWA T, MIGITA K, SHIGENO M, SAKAMOTO M et al. Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells. Hepatology 2002; 35: 1117-1124,
2. ACKERMAN RC, MURDOCH WJ. Prostaglandin-induced apoptosis of ovarian surface epithelial cells. Prostaglandins 1993; 45: 475-485.
3. AHMEDKHANOV A, TONIOLO P, ZELENIUCH-JACQUOTTE A, KATO I, KOENIG KL, SHORE RE. Aspirin and epithelial ovarian cancer. Prevent Med 2001; 33: 682-687,
4. ALBRECHT H, SCHOOK LB, JONGENEEL CV. Nuclear migration of Nf-kappa B correlates with TNF-alpha mRNA accumulation. J Inflamm 1995; 45: 64-71.
5. BACHER M, METZ CN, CALANDRA T, MAYER K, CHESNEY J, LOHOFFM et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 1996; 93: 7849-7854.
6. BARON JA, SANDLERS RS. Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu Rev Med 2000; 51: 511-523.
7. BERMAN KS, VERMA UN, HARBURG G, MINNA JD, COBB MH, GAYNOR RB. Sulindac enhances tumor necrosis factor-alpha-mediated apoptosis of lung cancer cell lines by inhibition of nuclear factor-kappaB. Clin Cancer Res 2002; 8: 354-356.
8. BERNHAGEN J, CALANDRA T, MITCHELL RA, MARTIN SB, TRACEY KJ et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 1993; 365: 756-759.
9. BEPPU M, IKEBE T, SHIRASUNA K. The inhibitory effects of immunosuppressive factors, dexamethasone and interleukin-4, on Nf-kappaB-mediated protease production by oral cancer. Biochim Biophys Acta 2002; 1586: 11-22.
10. BLOOM BR, BENNETT B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 1966; 153: 80-82.
11. BOURS V, DEJARDIN E, GOUJON-LETAWE F, MERVILLE P, CASTRONOVO V. The NF-kappaB transcription factor and cancer: high expression of NF-kappa B- and IkappaB-related proteins in tumor cell lines. Biochem Pharmacol 1994; 47: 145-149.
12. BOUTAUD O, ARONOFF DM, RICHARDSON JH, MARNETT L, OATES JA. Determinants of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H2 synthases. Proc Natl Acad Sci USA 2002; 99: 7130-7135.
13. BOTTING R. Paracetamol-inhibitable COX-2. J Physiol Pharmacol 2000; 51: 609-618.
14. BOZZA M, SATOSKAR AR, LIN G, LU B, HUMBLES AA et al. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 1999; 189: 341-346.
15. BRACH MA, GRUSS HJ, KAISHO T, ASANO Y, HIRANO T, HERRMANN F. Ionizing radiation induces expression of interleukin 6 by human fibroblasts involving activation of nuclear factor-kappa B. J Biol Chem 1993; 268: 8466-8472.
16. BRYAN EJ, THOMAS NA, PALMER K, DAWSON E, ENGLEFIELD P, CAMPBELL IG. Refinement of an ovarian cancer tumour suppressor gene locus on the chromosome arm 22q and mutation analysis of CYP2D6, SREBP2 and NAGA. Int J Cancer 2000; 87: 798-802.
17. CALANDRA T, BERNHAGEN J, METZ CN, SPIEGEL LA, BACHER M et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995; 377: 68-71.
18. CALANDRA T, BERNHAGEN J, MITCHELL RA, BUCALA R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994; 179: 1895-1902.
19. CALANDRA T, ECHTENACHER B, ROY DL, PUGIN J, METZ CN et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000; 6: 164-170.
20. CHANDRASEKHARAN NV, DAI H, ROOS LT, EVANSON NK, TOMSIK J et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure and expression. Proc Natl Acad Sci USA 2002; 99: 13926-13931.
21. CHESNEY J, METZ C, BACHER M, PENG P, MEINHARDT A, BUCALA R. An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med 1999; 5: 181-191.
22. COLLART MA, BAUERLE P, VASSALI P. Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four kappaB-like motifs and of constitutive and inducible forms of Nf-kappaB. Mol Cell Biol 1990; 10: 1498-1506.
23. CRAMER DW, HARLOW BL, TITUS-ERNSTHOFF L, BOHLKE K, WELCH WR, GREENBERG ER. Over-the-counter analgesics and risk of ovarian cancer. Lancet 1998; 351: 104-107.
24. CRAMER DW, LIBERMAN RF, HORNSTEIN MD, MCSHANE P, POWERS D et al. Basal hormone levels in women who use acetaminophen for menstrual pain. Fertil Steril 1998; 70: 371-373.
25. CRAMER DW, WELCH DR. Determinant of ovarian cancer risk, II: inferences regarding pathogenesis. J Natl Cancer Inst 1983; 71: 717-721.
26. DAUN JM, CANNON JG. Macrophage migration inhibitory factor antagonizes hydrocortisone-induced increases in cytosolic IkappaBalpha. Am J Physiol Regul Integr Comp Physiol 2000; 279: R1043-1049.
27. DAVID JR. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 1996; 56: 72-77.
28. DEL VECCHIO MT, TRIPODI SA, ARCURI F, PERGOLA L, HAKO L et al. Macrophage migration inhibitory factor in prostatic adenocarcinoma: correlation with tumor grading and combination endocrine treatment-related changes. Prostate 2000; 45: 51-57.
29. DENDORFER U, OETTGEN P, LIBERMANN TA. Interleukin-6 gene expression by prostaglandins and cyclic AMP mediated by multiple regulatory elements. Am J Ther 1995; 2: 660-665.
30. DONJERKOVIC D, MUELLER CM, SCOTT DW. Steroid- and retinoid-mediated growth arrest and apoptosis in WEHI-231 cells: Role of Nf-kappaB, c-myc and CK1 p27(kip1). Eur J Immunol 2000; 30: 1154-1161.
31. DONNELLY SC, HASLETT C, REID PT, GRANT IS, WALLACE WA et al. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med 1997; 3: 320-323.
32. DUFFEY DC, CHEN Z, DONG G, ONDREY FG, WOLF JS et al. Expression of a dominant-negative mutant inhibitor-kappa-Balpha of nuclear factor-kappaB inhibits survival, proinflammatory cytokine expression and tumor growth in vivo. Cancer Res 1999; 59: 3468-3474.
33. DRAKE JG, BECKER JL. Aspirin-induced growth inhibition of ovarian tumor cell growth. Obstetrics & Gynecology 2002; 100: 677-682.
34. FAHLBUSCH B, METZNER GI, SCHUMANN I, TITTEL R. Inhibition of macrophage migration by a factor from ascites fluids of ovarian cancer patients. 11. Production and characterization of an anti-MIF antibody. Biomed Biochim Acta. 1986; 45: 371-384.
35. FAHLBUSCH B, SCHUMANN I. Inhibition of macrophage migration by a factor from ascites fluids of ovarian cancer patients. III. Generation of monoclonal antibody specific for human MIF. Biomed Biochim Acta 1987; 46: 397-406.
36. FAHLBUSCH B, TITTEL R. Inhibition of macrophage migration by a factor from ascites fluids of ovarian cancer patients. I. Biochemical characterization and purification. Biomed Biochim Acta. 1986; 45: 359-370.
37. FAIRFIELD KM, HUNTER DJ, FUCHS CS, COLDITZ GA, HANKINSON SE. Aspirin, other NSAIDS, and ovarian cancer risk. Cancer Causes Control 2002; 13: 535-542.
38. FATHALLA MF. Incessant ovulation - A factor in ovarian neoplasia? Lancet 1971; 2: 163.
39. FLOWER RJ, VANE JR. Inhibition of prostaglandin synthase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature 1971; 240: 410-411.
40. FRIIS S, NIELSEN GL, MELLEMKJAER L, MCLAUGHLIN JK, THULSTRUP AM et al. Cancer risk in persons receiving prescriptions for paracetamol: A Danish cohort study. Int J Cancer 2002; 97: 96-101.
41. GILROY DW, COLVILLE-NASH PR, WILLIS D, CHIVERS J, PAUL-CLARK MJ, WILLOUGHBY DA. Inducible cyclooxygenase may have anti-inflammatory properties. Nature Med 1999; 5: 698-701.
42. GUPTA RA, TEJADA LV, TONG BJ, DAS SK, MORROW JD et al. Cyclooxygenase-1 is expressed and promotes angiogenic factor production in ovarian cancer. Cancer Res 2003; 63: 906-911.
43. GREENLEE RT, MURRAY T, BOLDEN S, WINGO PA. Cancer statistics. Ca Cancer J Clin 2000; 50: 7-33.
44. GROVE M, PLUMB M. C/EBP, NF-kappa B, and c-ets family members and transcriptional regulation of the cell-specific and inducible macrophage inflammatory protein 1 alpha immediate-early gene. Mol Cell Biol 1993; 13: 5276-5289.
45. HANEY AF, HUGHES SF, HUGHES CL. Effects of acetaminophen and non-steroidal antiinflammatory drugs on progesterone production by porcine granulosa cells in vitro. Reprod Toxicol 1987/88; 1: 285-291.
46. HOCHWALD SN, ROSE DM, BRENNAN MF, BURT ME. Elevation of glutathione and related enzyme activities in high-grade and metastatic extremity soft tissue sarcoma. Ann Surg Oncol 1997; 4: 303-309.
47. HUANG S, ROBINSON JB, DEGUZMAN A, BUCANA C, FIDLER IJ. Blockade of nuclear factor-KB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin-8. Cancer Res 2000; 60: 5334-5339.
48. HUDSON JD, SHOAIBI MA, MAESTRO R, CARNERO A, HANNON GJ, BEACH DH. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 1999; 190: 1375-1382.
49. IP C. Selenium inhibition of chemical carcinogenesis. Fed Proc 1985; 44: 2573-2578.
50. ISHIKAWA Y, SUGIYAMA H, STYLIANOU E, KITAMURA M. Bioflavonoid quercetin inhibits interleukin-1 induced transcriptional expression of monocyte chemoattractant protein-1 in glomerular cells via suppression of nuclear factor-kappaB. J Am Soc Nephrol 1999; 10: 2290-2296.
51. JOSHI PC, POOLE GV, SACHDEV V, ZHOU X, JONES Q. Trauma patients with positive cultures have higher levels of circulating macrophage migration inhibitory factor (MIF). Res Commun Mol Pathol Pharmacol 2000; 107: 13-20.
52. KOPP E, GHOSH S. Inhibition of Nf-KB by sodium salicylate and aspirin. Science 1994; 265: 956-959.
53. LAWSON JA, FISHER MA, SIMMONS CA, FARHOOD A, JAESCHKE H. Inhibition of fas receptor (CD95)-induced hepatic caspase activation and apoptosis by acetaminophen in mice. Toxicol Appl Pharmacol 1999; 156: 179-186.
54. LEUNG NWY, CRITCHLEY JAJH. Increased oxidative metabolism of paracetamol in patients with hepatocellular carcinoma. Cancer Letters 1991; 57: 45-48.
55. LIEBERMANN TA, BALTIMORE D. Activation of interleukin-6 gene expression through the NF-kappaB transcription factor. Mol Cell Biol 1990; 10: 2327-2334.
56. LOLIS E. Glucocorticoid counter regulation: macrophage migration inhibitory factor as a target for drug discovery. Curr Opin Pharmacol 2001; 1: 662-668.
57. LOUIE KG, BEHRENS BC, KINSELLA TJ, HAMILTON TC, GROTZINGER KR et al. Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res 1995; 45: 2110-2115.
58. LOUW DF, BOSE R, SIMA AA, SUTHERLAND GR. Evidence for a high free radical state in low-grade astrocytomas. Neurosurgery 1997; 41: 1146-1150.
59. LUKIW WJ, PELAEZ RP, MARTINEZ J, BAZAN NG. Budenoside epimer R or dexamethasone selectively inhibit platelet activating factor-induced or interleukin 1 beta-induced DNA binding activity of cis-transcription factors and cyclooxygenase-2 gene expression in human epidermal keratinocytes. Proc Natl Acad Sci USA 1998; 95: 3914-3919.
60. MARKERT JM, FULLER CM, GILLESPIE GY, BUBIEN JK, MCLEAN LA et al. Differential gene expression profiling in human brain tumors. Physiol Genomics 2001; 5: 21-33.
61. MALIK STA, GRIFFIN DB, FIERS W, BAKWILL FR. Paradoxical effects of tumor necrosis factors in experimental ovarian cancer. Int J Cancer 1989; 44: 918-925.
62. MARUMOTO T, SCHINI-KERN VB, BUSSE R. Vascular endothelial growth factor activates monocyte chemoattractant protein-1 in bovine retinal endothelial cells. Diabetes 1999; 48: 1131-1137.
63. MATSUO M, NAKAMURA N, SHIDOJI Y, MUTO Y, ESAKI H, OSAWA T. Antioxidative mechanism and apoptosis induction by 3-hydroxyanthranilic acid, an antioxidant in Indonesian food Tempeh, in the human hepatoma- derived cell line, HuH-7. J Nutr Sci Vitaminol (Tokyo) 1997; 43: 249-259.
64. MATSUURA T, SUGIMURA M, IWAKI T, OHASHI R, KANAYAMA N, NISHIHIRA J. Anti-macrophage inhibitory factor antibody inhibits PMSG-hCG-induced follicular growth and ovulation in mice. J Assist Reprod Genet 2002; 19: 591-595.
65. MAYNE ST, GRAHAM S, ZHENG TZ. Dietary retinol: prevention or promotion of carcinogenesis in humans? Cancer Causes Control 1991; 2: 443-450.
66. MCLAUGHLIN JK, BLOT WJ, MEHL ES, FRAUMENI JR JF. Relation of analgesic use to renal cancer: population-based findings. Natl Cancer Inst Monogr 1985; 69: 217-222.
67. MITCHELL JA, AKARASEREENONT P, THIEMERMANN C, FLOWER RJ, VANE JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1994; 90: 11693-11697.
68. MOYSICH KB, METTLIN C, PIVER PS, NATARAJAN N, MENEZES RJ, SWEDE H. Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiology Biomarkers and Prevention 2001; 10: 903-906.
69. MUNKARAH AR, MORRIS R, BAUMANN P, DEPPE G, MALONE J et al. Effect of prostaglandin E2 on proliferation and apoptosis of epithelial ovarian cancer. J Soc Gynecol Investig 2002: 9: 168-173.
70. MURDOCH WJ, LUND SA. Prostaglandin-independent anovulatory mechanism of indomethacin action: Inhibition of tumor necrosis factor alpha-induced sheep ovarian cell apoptosis. Biol Reprod 1999; 61: 1655-1659.
71. MURDOCH WJ, TOWNSEND RS, MCDONNEL AC. Ovulation-induced DNA damage in ovarian surface epithelial cells of ewes. Prospective regulatory mechanisms of repair/survival and apoptosis. Biol Reprod 2001; 65: 1417-1424.
72. NATIONAL TOXICOLOGY PROGRAM. Toxicology and carcinogenesis studies of acetaminophen (CAS No. 103-90-2) in F344/N rats and B6C3F1 mice (feed studies). Technical report series No. 394. NIH publication No. 92-3489. US. Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC, 1993.
73. NESS RB. Endometriosis and ovarian cancer: Thoughts on shared pathophysiology. Am J Obstet Gynecol 2003; 189: 280-294.
74. NESS RB, COTTREAU C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 1999; 91: 1459-1467.
75. OGAWA H, NISHIRA J, SATO Y, KONDO M, TAKAHASHI N et al. An antibody for macrophage migration inhibitory factor suppresses tumor growth and inhibits tumor-associated angiogenesis. Cytokine 2000; 12: 309-314.
76. ONODERA S, KANEDA K, MIZUE Y, KOYAMA Y, FUJINAGA M, NISHIHIRA J. Macrophage migration inhibitory factor upregulates expression of matrix metalloproteinases in synovial fibroblasts of rheumatoid arthritis. J Biol Chem 2000; 275: 444-450.
77. OUELLET M, PERCIVAL MD. Mechanism of acetaminophen inhibition of cyclooxygenase isoforms. Archiv Biochem Biophys 2001; 387: 273-280.
78. PALAYOOR ST, BUMP EA, CALDERWOOD SK, BARTOL S, COLEMAN CN. Combined antitumor effect of radiation and ibuprofen in human prostate carcinoma cells. Clin Cancer Res 1998; 4: 763-771.
79. PALAYOOR ST, TOFILON PJ, COLEMAN CN. Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1alpha and HIF-2alpha in prostate cancer cells. Clin Cancer Res 2003; 9: 3150-3157.
80. PALAYOOR ST, YOUMELL MY, CALDERWOOD SK, COLEMAN CN, PRICE BD. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 1999; 18: 7389-7394.
81. PATRICK L. Beta-carotene: the controversy continues. Altern Med Rev 2000; 5: 530-45.
82. QUIRK JT, KUPINSKI JM. Chronic infection, inflammation, and epithelial ovarian cancer. Med Hypotheses 2001; 57: 426-428.
83. REUNING U, WILHELM O, NISHIGUCHI T, GUERRINI L, BLASI F et al. Inhibition of Nf-kappa B-Rel A expression by antisense oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1. Nucleic Acids Res 1995; 23: 3887-3893.
84. RODRIGUEZ C, HENLEY SJ, CALLE EE, THUN MJ. Paracetamol and risk of ovarian cancer mortality in a prospective study of women in the USA, Lancet 1998; 352: 1354-1355.
85. ROSENBERG L, PALMER JR, RAO RS, COOGAN PF, STROM BL et al. A case-control study of analgesic use and ovarian cancer. Cancer Epidemiol Biomarker Prevent 2000; 9: 933-937.
86. RYU SY, LEE JH, SEOK JH, HONG JH, LEE YS et al. Acetaminophen inhibits iNOS gene expression in raw 264.7 macrophages: Differential regulation of Nf-KB by acetaminophen and salicylates. Biochem Biophys Res Commun 2000; 272: 758-764.
87. SAUNDERS DE, CHRISTIENSEN C, WAPLER NL, SCHULTZ JF, LAWRENS WV et al. Inhibition of c-myc in breast and ovarian carcinoma cells by 1,25-dihydroxyvitamin D3, retinoic acid and dexamethasone. Anticancer Drugs 1993; 4: 201-208.
88. SASAKI H, FUKUSHIMA M. Prostaglandins in the treatment of cancer. Anticancer Drugs 1994; 5: 131-138.
89. SCHWARTZ JL. The dual roles of nutrients as antioxidants and prooxidants: their effects on tumor cell growth. J Nutr 1996; 126: 1221S-1227S.
90. SCHUTYSER E, STRUYF S, PROOST P, OPDENAKKERT G, LAUREYS G et al. Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J Biol Chem 2002; 277: 24584-24593,
91. SCIULLI MG, SETA F, TACCONELLI S, CAPONE ML, RICCIOTTI E et al. Effects of acetaminophen on constitutive and inducible prostanoid biosynthesis in human blood cells. Brit J Pharmacol 2003; 138: 638-641.
92. SENTER PD, AL-ABED Y, METZ CN, BENIGNI F, MITCHELL RA et al. Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites. Proc Natl Acad Sci USA 2002; 99: 144-149.
93. SHIMIZU T, ABE R, NAKAMURA H, OHKAWARA A, SUZUKI M, NISHIHIRA J. High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis, Biochem Biophys Res Commun 1999; 264: 751-758.
94. SIMMONS DL, BOTTING RM, ROBERTSON PM, MADSEN ML, VANE JR. Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs. Proc Natl Acad Sci USA 1999; 96: 3275-3280.
95. SORENSEN HT, FRIIS S, NORGARD B, MELLEMKJAER L, BLOT WJ et al. Risk of cancer in a large cohort of nonaspirin NSAID users, a population-based study. Brit J Cancer 2003; 88: 1687-1692.
96. SPALLHOLZ JE. On the nature of selenium toxicity and carcinostatic activity. Free Radic Biol Med 1994; 17: 45-64.
97. SPREM M, BABIC D, ABRAMIC M, VRHOVEC I, SKRK J et al. Glutathione and glutathione S-transferases as early markers for ovarian carcinomas: case series. Croat Med J 2001; 42: 624-629.
98. STRATTON JA, BRALY PS, DISAIA PJ. Response of human adenocarcinoma to chemotherapy: as sole agents and in combination with sodium ibuprofen. Gynecol Oncol 1984; 18: 145-149.
99. TANABE T, TOHNAI N. Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat 2002; 68-69: 95-114.
100. TANNER B, HENGSTLER JG, DIETRICH B, HENRICH M, STEINBERG P et al. Glutathione, glutathione S-transferase alpha and pi, and aldehyde dehydrogenase content in relationship to drug resistance in ovarian cancer. Gynecol Oncol 1997;, 65: 54-62.
101. TAVANI A, GALLUS S, LA VECCHIA C, CONTI E, MONTELLA M, FRANCHESCI S. Aspirin and ovarian cancer: An Italian case-control study. Ann Oncol 2000; 11: 1171-1173.
102. TREDE NS, TSYTSYKOVA AV, CHATILA T, GOLDFELD AE, GEHA RS. Transcriptional activation of the human TNF-alpha promoter by superantigen in human monocytic cells: role of Nf-kappaB. J Immunol 1995; 155: 902-908.
103. TZONOU A, POLYCHRONOPOULOU A, HSIEH CC. Hair dyes, analgesics, tranquilizers, and perineal talc application as risk factors for ovarian cancer. Int J Cancer 1993; 55: 408-410.
104. UEDA A, ISHIGABUTSO Y, OKUBO T, YOSHIMURA T. Transcriptional regulation of the human monocyte chemoattractant protein-1 gene. Cooperation of two NF-kappaB sites and NF-kappaB/rel subunit specificity. J Biol Chem 1997; 272: 31092-31099.
105. UEDA A, OKUDA K, OHNO S, SHIRAI A, IGARASHI T et al. Nf-kappaB and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene. J Immunol 1994; 153: 2052-2063.
106. VANE JR, BOTTING RM. Anti-inflammatory drugs and their mechanism of action. Inflamm Res. 1998; 47: 78-87.
107. WADA S, FUJIMOTO S, MIZUE Y, NISHIHIRA J. Macrophage migration inhibitory factor in the human ovary: presence in the follicular fluids and production by granulosa cells. Biochem Mol Biol Int 1997; 41: 805-814.
108. WADA S, KUDO T, KUDO M, SAKURAGI N, HAREYAMA H et al. Induction of macrophage migration inhibitory factor in human ovary by human chorionic gonadotrophin. Hum Reprod 1999; 14: 395-399.
109. WATSON JM, SENSINT AFFAR JL, BEREK JS, MARTINEZ-MAZZA O. Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res 1990; 50: 6959-6965.
110. WU GY, WU CH, RUBIN MI. Acetaminophen hepatotoxicity and targeted rescue: A model for specific chemotherapy of hepatocellular carcinoma. Hepatology 1985; 5: 709-713.
111. YAMAMOTO K, ARAKAWA T, UEDA N, YAMAMOTO S. Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin 6 in the tumor necrosis alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J Biol Chem 1995; 270: 31315-31320.
112. ZHOU L, ERICKSON RR, HARDWICK JP, PARK SS, WRIGHTON SA, HOLTZMAN JL. Catalysis of the cyteine conjugation and protein binding of acetaminophen by microsomes from a human lymphoblast cell line transfected with the cDNAs of